AZN - Bullish on AstraZeneca cancer drug Cronos MSO stake not a big deal and more in analyst action

marchmeena29/iStock via Getty Images AstraZeneca bullish on Enhertu in upcoming studies BofA Securities talked with AstraZeneca (AZN) EVP, Oncology Dave Frederick who told the firm the company believes two upcoming studies on Enhertu (fam-trastuzumab deruxtecan-nxki) will boost use of the breast cancer biologic. One of the studies is examining the monoclonal antibody vs. Roche's Kadcyla (ado-trastuzumab-emtasine) for second-line HER2 breast cancer. The other is Enhertu in HER2-low patients. Frederick also said that data from the TROPION 2 and 4 studies of DS1062, which AstraZeneca is developing with Daiichi Sankyo, could allow for the start of a phase 3 trial of the candidate as a first-line treatment for non-small cell lung cancer. Despite stake in MSO, BoA sees Cronos as an underperformer Although Cronos Group (CRON) yesterday announced it was taking a 10.5% stake in private multi-state operator PharmaCann, BoA analyst Heather Balsky is maintaining her underperform raring and on $6.50

For further details see:

Bullish on AstraZeneca cancer drug, Cronos MSO stake not a big deal, and more in analyst action